Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
24 mai 2018 08h00 HE
|
Immune Design Corp.
-- 1st global Phase 3 trial focused on synovial sarcoma patients -- www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Immune...
Immune Design’s GLAAS™ Platform Shown to Modulate the Allergic Immune Response
04 mars 2016 08h00 HE
|
Immune Design Corp.
Establishes Potential for the Treatment of Pollen and Peanut Allergies Data Presented at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting SEATTLE and SOUTH...
Immune Design to Report Fourth Quarter and Year End 2015 Financial Results
03 mars 2016 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, March 03, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth...
Immune Design to Present at Cowen and Company 36th Annual Health Care Conference
29 févr. 2016 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya,...
Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates
09 févr. 2016 08h00 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported positive topline...
Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305
08 janv. 2016 15h42 HE
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S....